Ovulation Induction

  • Mark GibsonEmail author


Induction of ovulation is primarily used for treatment of infertility in anovulatory women. Long-term management of anovulatory states may result in incidental or intended establishment of regular ovulation when fertility is not a goal, for example, when insulin-enhancing agents or dopamine agonists are administered to women with polycystic ovary syndrome (PCOS) or hyperprolactinemia, respectively. This chapter will focus specifically on induction of ovulation for women who desire restoration of ovulation for the purpose of becoming pregnant.

Induction of ovulation for fertility treatment should be undertaken with awareness of other potential fertility factors affecting the likelihood of conception. Most important among these are tubal patency and semen quality, and ideally these should be evaluated prior to therapy. This is certainly true in the case of treatments entailing substantial cost and disruption for the patient such as administration of gonadotropins. In practice, when the history is convincing that the male and tubal factors are very likely normal, and treatment is of lesser intensity and cost, evaluation of male and tubal factors may be delayed until after a few cycles of successful ovulation have occurred without conception.


Ovulation induction Anovulation Gonadotropin Clomiphene citrate Luteinizing hormone Obesity PCOS Cancer 


  1. 1.
    Shepard MK, Balmaceda JP, Leija CG (1979) Relationship of weight to successful induction of ovulation with clomiphene citrate. Fertil Steril 32(6):641-645PubMedGoogle Scholar
  2. 2.
    Balen AH, Platteau P, Andersen AN et al (2006) The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization group II anovulatory infertility. BJOG 113(10):1195-1202PubMedCrossRefGoogle Scholar
  3. 3.
    Galtier-Dereure F, Pujol P, Dewailly D, Bringer J (1997) Choice of stimulation in polycystic ovarian syndrome: the influence of obesity. Hum Reprod 12 Suppl 1:88-96PubMedGoogle Scholar
  4. 4.
    Palomba S, Falbo A, Orio F Jr, Tolino A, Zullo F (2009) Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome. Fertil Steril 91(6):2557-2567PubMedCrossRefGoogle Scholar
  5. 5.
    Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ (1998) Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 13(6):1502-1505PubMedCrossRefGoogle Scholar
  6. 6.
    Guzick DS (2004) Polycystic ovary syndrome. Obstet Gynecol 103(1):181-193PubMedGoogle Scholar
  7. 7.
    Guzick DS (2007) Ovulation induction management of PCOS. Clin Obstet Gynecol 50(1):255-267PubMedCrossRefGoogle Scholar
  8. 8.
    Clark AM, Ledger W, Galletly C et al (1995) Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 10(10):2705-2712PubMedGoogle Scholar
  9. 9.
    Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS (2004) A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 82(2):421-429PubMedCrossRefGoogle Scholar
  10. 10.
    Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millan JL (2005) The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 90(12):6364-6369PubMedCrossRefGoogle Scholar
  11. 11.
    Hamilton-Fairley D, Kiddy D, Watson H, Paterson C, Franks S (1992) Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br J Obstet Gynaecol 99(2):128-131PubMedGoogle Scholar
  12. 12.
    Lashen H, Fear K, Sturdee DW (2004) Obesity is associated with increased risk of first trimester and recurrent miscarriage: matched case-control study. Hum Reprod 19(7):1644-1646PubMedCrossRefGoogle Scholar
  13. 13.
    Metwally M, Ledger WL, Li TC (2008) Reproductive endocrinology and clinical aspects of obesity in women. Ann N Y Acad Sci 1127:140-146PubMedCrossRefGoogle Scholar
  14. 14.
    Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2008) Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 89(3):505-522CrossRefGoogle Scholar
  15. 15.
    Gysler M, March CM, Mishell DR Jr, Bailey EJ (1982) A decade’s experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril 37(2):161-167PubMedGoogle Scholar
  16. 16.
    Gerhard I, Runnebaum B (1979) Comparison between tamoxifen and clomiphene therapy in women with anovulation. Arch Gynecol 227(4):279-288PubMedCrossRefGoogle Scholar
  17. 17.
    Beck JI, Boothroyd C, Proctor M, Farquhar C, Hughes E (2005) Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database Syst Rev 1:CD002249Google Scholar
  18. 18.
    Glasier AF, Irvine DS, Wickings EJ, Hillier SG, Baird DT (1989) A comparison of the effects on follicular development between clomiphene citrate, its two separate isomers and spontaneous cycles. Hum Reprod 4(3):252-256PubMedGoogle Scholar
  19. 19.
    Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ (1986) Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril 46(3):392-396PubMedGoogle Scholar
  20. 20.
    Turner RT, Evans GL, Sluka JP et al (1998) Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene, and zuclomiphene. Endocrinology 139(9):3712-3720PubMedCrossRefGoogle Scholar
  21. 21.
    Opsahl MS, Robins ED, O’Connor DM, Scott RT, Fritz MA (1996) Characteristics of gonadotropin response, follicular development, and endometrial growth and maturation across consecutive cycles of clomiphene citrate treatment. Fertil Steril 66(4):533-539PubMedGoogle Scholar
  22. 22.
    Clark JH, Guthrie SC (1981) Agonistic and antagonistic effects of clomiphene citrate and its isomers. Biol Reprod 25(3):667-672PubMedCrossRefGoogle Scholar
  23. 23.
    Adashi EY (1984) Clomiphene citrate: mechanism(s) and site(s) of action - a hypothesis revisited. Fertil Steril 42(3):331-344PubMedGoogle Scholar
  24. 24.
    Olsson JH, Granberg S (1990) Effect of clomiphene isomers on oestradiol synthesis in cultured human granulosa cells. Hum Reprod 5(8):928-932PubMedGoogle Scholar
  25. 25.
    Zhuang LZ, Adashi EY, Hsuch AJ (1982) Direct enhancement of gonadotropin-stimulated ovarian estrogen biosynthesis by estrogen and clomiphene citrate. Endocrinology 110(6):2219-2221PubMedCrossRefGoogle Scholar
  26. 26.
    Schwartz LB, Brezinski A, Laufer N (1993) The effect of clomiphene citrate isomers on human granulosa-lutein cells in culture. Gynecol Endocrinol 7(4):229-233PubMedCrossRefGoogle Scholar
  27. 27.
    Hata T, Yoshino K, Nagahara Y, Matsunaga I, Kitao M (1983) Precise day of ovulation determined by real-time ultrasound evidence of graafian follicular development. Int J Gynaecol Obstet 21(6):435-438PubMedCrossRefGoogle Scholar
  28. 28.
    Haritha S, Rajagopalan G (2003) Follicular growth, endometrial thickness, and serum estradiol levels in spontaneous and clomiphene citrate-induced cycles. Int J Gynaecol Obstet 81(3):287-292PubMedGoogle Scholar
  29. 29.
    Fossum GT, Vermesh M, Kletzky OA (1990) Biochemical and biophysical indices of follicular development in spontaneous and stimulated ovulatory cycles. Obstet Gynecol 75(3 Part 1):407-411PubMedGoogle Scholar
  30. 30.
    Wu CH, Winkel CA (1989) The effect of therapy initiation day on clomiphene citrate therapy. Fertil Steril 52(4):564-568PubMedGoogle Scholar
  31. 31.
    Dehbashi S, Vafaei H, Parsanezhad MD, Alborzi S (2006) Time of initiation of clomiphene citrate and pregnancy rate in polycystic ovarian syndrome. Int J Gynaecol Obstet 93(1):44-48PubMedCrossRefGoogle Scholar
  32. 32.
    Adams R, Mishell DR Jr, Israel R (1972) Treatment of refractory anovulation with increased dosage and prolonged duration of cyclic clomiphene citrate. Obstet Gynecol 39(4):562-566PubMedGoogle Scholar
  33. 33.
    Fluker MR, Wang IY, Rowe TC (1996) An extended 10-day course of clomiphene citrate (CC) in women with CC-resistant ovulatory disorders. Fertil Steril 66(5):761-764PubMedGoogle Scholar
  34. 34.
    O’Herlihy C, Evans JH, Brown JB, de Crespigny LJ, Robinson HP (1982) Use of ultrasound in monitoring ovulation induction with human pituitary gonadotropins. Obstet Gynecol 60(5):577-582PubMedGoogle Scholar
  35. 35.
    Andersen AG, Als-Nielsen B, Hornnes PJ, Franch Andersen L (1995) Time interval from human chorionic gonadotrophin (HCG) injection to follicular rupture. Hum Reprod 1995;10(12):3202-3205PubMedGoogle Scholar
  36. 36.
    Fischer RA, Nakajima ST, Gibson M, Brumsted JR (1993) Ovulation after intravenous and intramuscular human chorionic gonadotropin. Fertil Steril 60(3):418-422PubMedGoogle Scholar
  37. 37.
    Eden JA, Place J, Carter GD, Jones J, Alaghband-Zadeh J, Pawson ME (1989) The effect of clomiphene citrate on follicular phase increase in endometrial thickness and uterine volume. Obstet Gynecol 73(2):187-190PubMedGoogle Scholar
  38. 38.
    Dehbashi S, Parsanezhad ME, Alborzi S, Zarei A (2003) Effect of clomiphene citrate on endometrium thickness and echogenic patterns. Int J Gynaecol Obstet 80(1):49-53PubMedCrossRefGoogle Scholar
  39. 39.
    Palomba S, Russo T, Orio F Jr et al (2006) Uterine effects of clomiphene citrate in women with polycystic ovary syndrome: a prospective controlled study. Hum Reprod 21(11):2823-2829PubMedCrossRefGoogle Scholar
  40. 40.
    Fedele L, Brioschi D, Marchini M, Dorta M, Parazzini F (1989) Enhanced preovulatory progesterone levels in clomiphene citrate-induced cycles. J Clin Endocrinol Metab 69(3):681-683PubMedCrossRefGoogle Scholar
  41. 41.
    Dickey RP, Taylor SN, Curole DN, Rye PH, Lu PY, Pyrzak R (1997) Relationship of clomiphene dose and patient weight to successful treatment. Hum Reprod 12(3):449-453PubMedCrossRefGoogle Scholar
  42. 42.
    Check JH, Dietterich C, Lurie D (1995) The effect of consecutive cycles of clomiphene citrate therapy on endometrial thickness and echo pattern. Obstet Gynecol 86(3):341-345PubMedCrossRefGoogle Scholar
  43. 43.
    Kolibianakis EM, Zikopoulos KA, Fatemi HM et al (2004) Endometrial thickness cannot predict ongoing pregnancy achievement in cycles stimulated with clomiphene citrate for intrauterine insemination. Reprod Biomed Online 8(1):115-118PubMedCrossRefGoogle Scholar
  44. 44.
    Unfer V, Costabile L, Gerli S, Papaleo E, Marelli G, Di Renzo GC (2001) Low dose of ethinyl estradiol can reverse the antiestrogenic effects of clomiphene citrate on endometrium. Gynecol Obstet Invest 51(2):120-123PubMedCrossRefGoogle Scholar
  45. 45.
    Gerli S, Gholami H, Manna C, Di Frega AS, Vitiello C, Unfer V (2000) Use of ethinyl estradiol to reverse the antiestrogenic effects of clomiphene citrate in patients undergoing intrauterine insemination: a comparative, randomized study. Fertil Steril 73(1):85-89PubMedCrossRefGoogle Scholar
  46. 46.
    Frattarelli JL, Dempsey MS (2004) Characteristics of baseline ovarian cysts in clomiphene citrate ovulation cycles. Fertil Steril 82(4):979-981PubMedCrossRefGoogle Scholar
  47. 47.
    Ben-Ami M, Geslevich Y, Battino S, Matilsky M, Shalev E (1993) Management of functional ovarian cysts after induction of ovulation. A randomized prospective study. Acta Obstet Gynecol Scand 72(5):396-397PubMedCrossRefGoogle Scholar
  48. 48.
    MacKenna A, Fabres C, Alam V, Morales V (2000) Clinical management of functional ovarian cysts: a prospective and randomized study. Hum Reprod 15(12):2567-2569PubMedCrossRefGoogle Scholar
  49. 49.
    Csokmay JM, Frattarelli JL (2006) Basal ovarian cysts and clomiphene citrate ovulation induction cycles. Obstet Gynecol 107(6):1292-1296PubMedGoogle Scholar
  50. 50.
    Blenner JL (1991) Clomiphene-induced mood swings. J Obstet Gynecol Neonatal Nurs 20(4):321-327PubMedCrossRefGoogle Scholar
  51. 51.
    Choi SH, Shapiro H, Robinson GE et al (2005) Psychological side-effects of clomiphene citrate and human menopausal gonadotrophin. J Psychosom Obstet Gynaecol 26(2):93-100PubMedCrossRefGoogle Scholar
  52. 52.
    Purvin VA (1995) Visual disturbance secondary to clomiphene citrate. Arch Ophthalmol 113(4):482-484PubMedGoogle Scholar
  53. 53.
    Lawton AW (1994) Optic neuropathy associated with clomiphene citrate therapy. Fertil Steril 61(2):390-391PubMedGoogle Scholar
  54. 54.
    Dickey RP, Taylor SN, Curole DN, Rye PH, Pyrzak R (1996) Incidence of spontaneous abortion in clomiphene pregnancies. Hum Reprod 11(12):2623-2628PubMedGoogle Scholar
  55. 55.
    Legro RS, Barnhart HX, Schlaff WD et al (2007) Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356(6):551-566PubMedCrossRefGoogle Scholar
  56. 56.
    Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F (2006) Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 332(7556):1485PubMedCrossRefGoogle Scholar
  57. 57.
    Whiteman D, Murphy M, Hey K, O’Donnell M, Goldacre M (2000) Reproductive factors, subfertility, and risk of neural tube defects: a case-control study based on the Oxford Record Linkage Study Register. Am J Epidemiol 152(9):823-828PubMedCrossRefGoogle Scholar
  58. 58.
    Zhu JL, Basso O, Obel C, Bille C, Olsen J (2006) Infertility, infertility treatment, and congenital malformations: Danish national birth cohort. BMJ 333(7570):679PubMedCrossRefGoogle Scholar
  59. 59.
    Ahlgren M, Kallen B, Rannevik G (1976) Outcome of pregnancy after clomiphene therapy. Acta Obstet Gynecol Scand 55(4):371-375PubMedCrossRefGoogle Scholar
  60. 60.
    Correy JF, Marsden DE, Schokman FC (1982) The outcome of pregnancy resulting from clomiphene-induced ovulation. Aust N Z J Obstet Gynaecol 22(1):18-21PubMedCrossRefGoogle Scholar
  61. 61.
    Tulandi T, Martin J, Al-Fadhli R et al (2006) Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 85(6):1761-1765PubMedCrossRefGoogle Scholar
  62. 62.
    Elizur SE, Tulandi T (2008) Drugs in infertility and fetal safety. Fertil Steril 89(6):1595-1602PubMedCrossRefGoogle Scholar
  63. 63.
    Wu YW, Croen LA, Henning L, Najjar DV, Schembri M, Croughan MS (2006) Potential association between infertility and spinal neural tube defects in offspring. Birth Defects Res A Clin Mol Teratol 76(10):718-722PubMedCrossRefGoogle Scholar
  64. 64.
    Thatcher SS, Jackson EM (2006) Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil Steril 85(4):1002-1009PubMedCrossRefGoogle Scholar
  65. 65.
    Basso O, Baird DD (2003) Infertility and preterm delivery, birthweight, and Caesarean section: a study within the Danish National Birth Cohort. Hum Reprod 18(11):2478-2484PubMedCrossRefGoogle Scholar
  66. 66.
    Dickey RP (2007) The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society for Assisted Reproductive Technology/American Society for Reproductive Medicine recommendation to limit the number of embryos transferred. Fertil Steril 88(6):1554-1561PubMedCrossRefGoogle Scholar
  67. 67.
    Dickey RP, Taylor SN, Lu PY, Sartor BM, Rye PH, Pyrzak R (2005) Risk factors for high-order multiple pregnancy and multiple birth after controlled ovarian hyperstimulation: results of 4, 062 intrauterine insemination cycles. Fertil Steril 83(3):671-683PubMedCrossRefGoogle Scholar
  68. 68.
    Dickey RP, Taylor SN, Lu PY, Sartor BM, Rye PH, Pyrzak R (2001) Relationship of follicle numbers and estradiol levels to multiple implantation in 3, 608 intrauterine insemination cycles. Fertil Steril 75(1):69-78PubMedCrossRefGoogle Scholar
  69. 69.
    Hull ME, Moghissi KS, Magyar DM, Hayes MF, Zador I, Olson JM (1986) Correlation of serum estradiol levels and ultrasound monitoring to assess follicular maturation. Fertil Steril 46(1):42-45PubMedGoogle Scholar
  70. 70.
    Lobo RA, Paul W, March CM, Granger L, Kletzky OA (1982) Clomiphene and dexamethasone in women unresponsive to clomiphene alone. Obstet Gynecol 60(4):497-501PubMedGoogle Scholar
  71. 71.
    Daly DC, Walters CA, Soto-Albors CE, Tohan N, Riddick DH (1984) A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril 41(6):844-848PubMedGoogle Scholar
  72. 72.
    Singh KB, Dunnihoo DR, Mahajan DK, Bairnsfather LE (1992) Clomiphene-dexamethasone treatment of clomiphene-resistant women with and without the polycystic ovary syndrome. J Reprod Med 37(3):215-218PubMedGoogle Scholar
  73. 73.
    Diamant YZ, Evron S (1981) Induction of ovulation by combined clomiphene citrate and dexamethasone treatment in clomiphene citrate nonresponders. Eur J Obstet Gynecol Reprod Biol 11(5):335-340PubMedCrossRefGoogle Scholar
  74. 74.
    Trott EA, Plouffe L Jr, Hansen K, Hines R, Brann DW, Mahesh VB (1996) Ovulation induction in clomiphene-resistant anovulatory women with normal dehydroepiandrosterone sulfate levels: beneficial effects of the addition of dexamethasone during the follicular phase. Fertil Steril 66(3):484-486PubMedGoogle Scholar
  75. 75.
    Parsanezhad ME, Alborzi S, Motazedian S, Omrani G (2002) Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial. Fertil Steril 78(5):1001-1004PubMedCrossRefGoogle Scholar
  76. 76.
    Elnashar A, Abdelmageed E, Fayed M, Sharaf M (2006) Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod 21(7):1805-1808PubMedCrossRefGoogle Scholar
  77. 77.
    Neveu N, Granger L, St-Michel P, Lavoie HB (2007) Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertil Steril 87(1):113-120PubMedCrossRefGoogle Scholar
  78. 78.
    Khorram O, Helliwell JP, Katz S, Bonpane CM, Jaramillo L (2006) Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertil Steril 85(5):1448-1451PubMedCrossRefGoogle Scholar
  79. 79.
    Kocak M, Caliskan E, Simsir C, Haberal A (2002) Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 77(1):101-106PubMedCrossRefGoogle Scholar
  80. 80.
    Lord JM, Flight IH, Norman RJ (2003) Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 3:CD003053Google Scholar
  81. 81.
    Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R (1998) Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338(26):1876-1880PubMedCrossRefGoogle Scholar
  82. 82.
    Palomba S, Orio F Jr, Falbo A et al (2005) Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 90(7):4068-4074PubMedCrossRefGoogle Scholar
  83. 83.
    Palomba S, Orio F Jr, Nardo LG et al (2004) Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 89(10):4801-4809PubMedCrossRefGoogle Scholar
  84. 84.
    Kumari AS, Haq A, Jayasundaram R, Abdel-Wareth LO, Al Haija SA, Alvares M (2005) Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod Biomed Online 10(1):100-104PubMedCrossRefGoogle Scholar
  85. 85.
    Liu KE, Tataryn IV, Sagle M (2006) Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance. J Obstet Gynaecol Can 28(7):595-599PubMedGoogle Scholar
  86. 86.
    De Leo V, la Marca A, Petraglia F (2003) Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24(5):633-667PubMedCrossRefGoogle Scholar
  87. 87.
    Heard MJ, Pierce A, Carson SA, Buster JE (2002) Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril 77(4):669-673PubMedCrossRefGoogle Scholar
  88. 88.
    Azziz R, Ehrmann D, Legro RS et al (2001) Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86(4):1626-1632PubMedCrossRefGoogle Scholar
  89. 89.
    Rouzi AA, Ardawi MS (2006) A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 85(2):428-435PubMedCrossRefGoogle Scholar
  90. 90.
    Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW (2003) Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 79(3):562-566PubMedCrossRefGoogle Scholar
  91. 91.
    Barbieri RL (2003) Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol 101(4):785-793PubMedCrossRefGoogle Scholar
  92. 92.
    Cataldo NA, Barnhart HX, Legro RS et al (2008) Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. J Clin Endocrinol Metab 93(8):3124-3127PubMedCrossRefGoogle Scholar
  93. 93.
    Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE (2001) Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 75(2):310-315PubMedCrossRefGoogle Scholar
  94. 94.
    Siebert TI, Kruger TF, Steyn DW, Nosarka S (2006) Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review. Fertil Steril 86(5):1432-1437PubMedCrossRefGoogle Scholar
  95. 95.
    Creanga AA, Bradley HM, McCormick C, Witkop CT (2008) Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol 111(4):959-968PubMedGoogle Scholar
  96. 96.
    Sinawat S, Buppasiri P, Lumbiganon P, Pattanittum P (2008) Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS. Cochrane Database Syst Rev 1:CD006226Google Scholar
  97. 97.
    Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE (2002) Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87(2):524-529PubMedCrossRefGoogle Scholar
  98. 98.
    Branigan EF, Estes MA (1999) Treatment of chronic anovulation resistant to clomiphene citrate (CC) by using oral contraceptive ovarian suppression followed by repeat CC treatment. Fertil Steril 71(3):544-546PubMedCrossRefGoogle Scholar
  99. 99.
    Branigan EF, Estes MA (2003) A randomized clinical trial of treatment of clomiphene citrate-resistant anovulation with the use of oral contraceptive pill suppression and repeat clomiphene citrate treatment. Am J Obstet Gynecol 188(6):1424-1428; discussion 9-30PubMedCrossRefGoogle Scholar
  100. 100.
    Martin TL, Kim M, Malarkey WB (1985) The natural history of idiopathic hyperprolactinemia. J Clin Endocrinol Metab 60(5):855-858PubMedCrossRefGoogle Scholar
  101. 101.
    Bayram N, van Wely M, van der Veen F (2006) Pulsatile gonadotrophin releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome (review). Cochrane Collab 4:1-18Google Scholar
  102. 102.
    Buzdar AU (2003) Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res 9(1 Part 2):468S-472SPubMedGoogle Scholar
  103. 103.
    Mitwally MF, Biljan MM, Casper RF (2005) Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 192(2):381-386PubMedCrossRefGoogle Scholar
  104. 104.
    Badawy A, Mosbah A, Shady M (2008) Anastrozole or letrozole for ovulation induction in clomiphene-resistant women with polycystic ovarian syndrome: a prospective randomized trial. Fertil Steril 89(5):1209-1212PubMedCrossRefGoogle Scholar
  105. 105.
    Atay V, Cam C, Muhcu M, Cam M, Karateke A (2006) Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int Med Res 34(1):73-76PubMedGoogle Scholar
  106. 106.
    Begum MR, Ferdous J, Begum A, Quadir E (2009) Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. Fertil Steril 92(3):853-857PubMedCrossRefGoogle Scholar
  107. 107.
    Casper RF (2009) Letrozole versus clomiphene citrate: which is better for ovulation induction? Fertil Steril 92(3):858-859PubMedCrossRefGoogle Scholar
  108. 108.
    Bayar U, Basaran M, Kiran S, Coskun A, Gezer S (2006) Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial. Fertil Steril 86(5):1447-1451PubMedCrossRefGoogle Scholar
  109. 109.
    Badawy A, Aal IA, Abulatta M (2009) Clomiphene citrate or anastrozole for ovulation induction in women with polycystic ovary syndrome? A prospective controlled trial. Fertil Steril 92(3):860-863PubMedCrossRefGoogle Scholar
  110. 110.
    Badawy A, Metwally M, Fawzy M (2007) Randomized controlled trial of three doses of letrozole for ovulation induction in patients with unexplained infertility. Reprod Biomed Online 14(5):559-562PubMedCrossRefGoogle Scholar
  111. 111.
    Fisher SA, Reid RL, Van Vugt DA, Casper RF (2002) A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertil Steril 78(2):280-285PubMedCrossRefGoogle Scholar
  112. 112.
    Bayar U, Tanriverdi HA, Barut A, Ayoglu F, Ozcan O, Kaya E (2006) Letrozole vs. clomiphene citrate in patients with ovulatory infertility. Fertil Steril 85(4):1045-1048PubMedCrossRefGoogle Scholar
  113. 113.
    Elnashar A, Fouad H, Eldosoky M, Saeid N (2006) Letrozole induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome may not depend on the period of infertility, the body mass index, or the luteinizing hormone/follicle-stimulating hormone ratio. Fertil Steril 85(2):511-513PubMedCrossRefGoogle Scholar
  114. 114.
    Wu HH, Wang NM, Cheng ML, Hsieh JN (2007) A randomized comparison of ovulation induction and hormone profile between the aromatase inhibitor anastrozole and clomiphene citrate in women with infertility. Gynecol Endocrinol 23(2):76-81PubMedCrossRefGoogle Scholar
  115. 115.
    Farquhar CM, Williamson K, Brown PM, Garland J (2004) An economic evaluation of laparoscopic ovarian diathermy versus gonadotrophin therapy for women with clomiphene citrate resistant polycystic ovary syndrome. Hum Reprod 19(5):1110-1115PubMedCrossRefGoogle Scholar
  116. 116.
    Farquhar CM, Williamson K, Gudex G, Johnson NP, Garland J, Sadler L (2002) A randomized controlled trial of laparoscopic ovarian diathermy versus gonadotropin therapy for women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 78(2):404-411PubMedCrossRefGoogle Scholar
  117. 117.
    Kaya H, Sezik M, Ozkaya O (2005) Evaluation of a new surgical approach for the treatment of clomiphene citrate-resistant infertility in polycystic ovary syndrome: laparoscopic ovarian multi-needle intervention. J Minim Invasive Gynecol 12(4):355-358PubMedCrossRefGoogle Scholar
  118. 118.
    Armar NA, Lachelin GC (1993) Laparoscopic ovarian diathermy: an effective treatment for anti-oestrogen resistant anovulatory infertility in women with the polycystic ovary syndrome. Br J Obstet Gynaecol 100(2):161-164PubMedGoogle Scholar
  119. 119.
    Farhi J, Soule S, Jacobs HS (1995) Effect of laparoscopic ovarian electrocautery on ovarian response and outcome of treatment with gonadotropins in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril 64(5):930-935PubMedGoogle Scholar
  120. 120.
    Api M, Gorgen H, Cetin A (2005) Laparoscopic ovarian drilling in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 119(1):76-81PubMedCrossRefGoogle Scholar
  121. 121.
    Badawy A, Khiary M, Ragab A, Hassan M, Sherief L (2009) Ultrasound-guided transvaginal ovarian needle drilling (UTND) for treatment of polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 91(4):1164-1167PubMedCrossRefGoogle Scholar
  122. 122.
    Malkawi HY, Qublan HS, Hamaideh AH (2003) Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. J Obstet Gynaecol 23(3):289-293PubMedCrossRefGoogle Scholar
  123. 123.
    Saleh AM, Khalil HS (2004) Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 83(7):614-621PubMedGoogle Scholar
  124. 124.
    Kandil M, Selim M (2005) Hormonal and sonographic assessment of ovarian reserve before and after laparoscopic ovarian drilling in polycystic ovary syndrome. BJOG 112(10):1427-1430PubMedCrossRefGoogle Scholar
  125. 125.
    Seppala M, Hibroven E, Ranta T, Virkkunen P, Leppaluoto J (1975) Raised serum prolactin levels in amenorrhoea. Br Med J 2(5966):305-306PubMedCrossRefGoogle Scholar
  126. 126.
    L’Hermite M, Hotton F, Kleiner S, Caufriez A, Robyn C (1977) Amenorrhoea, sterility and hyperprolactinaemia. Importance of complex movement tomographic x-ray study and follow-up of the sella turcica. Ann Endocrinol 38(4):327-332Google Scholar
  127. 127.
    Davajan V, Kletzky O, March CM, Roy S, Mishell DR Jr (1978) The significance of galactorrhea in patients with normal menses, oligomenorrhea, and secondary amenorrhea. Am J Obstet Gynecol 130(8):894-904PubMedGoogle Scholar
  128. 128.
    Marrs RP, Kletzky OA, Teal J, Davajan V, March C, Mishell DR Jr (1979) Comparison of serum prolactin, plain radiography, and hypocycloidal tomography of the sella turcica in patients with galactorrhea. Am J Obstet Gynecol 135(4):467-469PubMedGoogle Scholar
  129. 129.
    Keye WR, Jr., Chang RJ, Wilson CB, Jaffe RB (1980) Prolactin-secreting pituitary adenomas. III. Frequency and diagnosis in amenorrhea-galactorrhea. JAMA 244(12):1329-1332Google Scholar
  130. 130.
    Crosignani PG, Ferrari C, Scarduelli C, Picciotti MC, Caldara R, Malinverni A (1981) Spontaneous and induced pregnancies in hyperprolactinemic women. Obstet Gynecol 58(6):708-713PubMedGoogle Scholar
  131. 131.
    Bergh T, Nillius SJ, Wide L (1978) Bromocriptine treatment of 42 hyperprolactinaemic women with secondary amenorrhoea. Acta Endocrinol 88(3):435-451PubMedGoogle Scholar
  132. 132.
    Franks S, Murray MA, Jequier AM, Steele SJ, Nabarro JD, Jacobs HS (1975) Incidence and significance of hyperprolactinaemia in women with amenorrhea. Clin Endocrinol 4(6):597-607CrossRefGoogle Scholar
  133. 133.
    Mroueh AM, Siler-Khodr TM (1977) Bromocryptine therapy in cases of amenorrhea-galactorrhea. Am J Obstet Gynecol 127(3):291-298PubMedGoogle Scholar
  134. 134.
    Hardy J (1979) The transsphenoidal surgical approach to the pituitary. Hosp Pract 14(6):81-89PubMedGoogle Scholar
  135. 135.
    Franks S (1979) Use of bromocriptine in hyperprolactinaemic anovulation and related disorders. Drugs 17(5):337-348PubMedCrossRefGoogle Scholar
  136. 136.
    Ampudia X, Puig-Domingo M, Schwarzstein D et al (1992) Outcome and long-term effects of pregnancy in women with hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 46(2-3):101-107PubMedCrossRefGoogle Scholar
  137. 137.
    Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68(2):412-418PubMedCrossRefGoogle Scholar
  138. 138.
    Weil C (1986) The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Curr Med Res Opin 10(3):172-195PubMedGoogle Scholar
  139. 139.
    Pepperell RJ, Martinez C, Dickinson A (1983) Natural history of patients with hyperprolactinaemia. Clin Reprod Fertil 2(4):237-247PubMedGoogle Scholar
  140. 140.
    Bergh T, Nillius SJ, Larsson SG, Wide L (1981) Effects of bromocriptine-induced pregnancy on prolactin-secreting pituitary tumours. Acta Endocrinol 98(3):333-338PubMedGoogle Scholar
  141. 141.
    Isaacs AJ (1979) Resolution of hyperprolactinaemia after bromocriptine-induced pregnancy. Lancet 1(8119):784-785PubMedCrossRefGoogle Scholar
  142. 142.
    Zarate A, Canales ES, Alger M, Forsbach G (1979) The effect of pregnancy and lactation on pituitary prolactin-secreting tumours. Acta Endocrinol 92(3):407-412PubMedGoogle Scholar
  143. 143.
    Jewelewicz R, Vande Wiele RL (1980) Clinical course and outcome of pregnancy in twenty-five patients with pituitary microadenomas. Am J Obstet Gynecol 136(3):339-343PubMedGoogle Scholar
  144. 144.
    Weinstein D, Yarkoni S, Schenker JG et al (1981) Conservative management of suspected prolactin secreting pituitary adenoma during pregnancy. Eur J Obstet Gynecol Reprod Biol 11(5):305-312PubMedCrossRefGoogle Scholar
  145. 145.
    Maeda T, Ushiroyama T, Okuda K, Fujimoto A, Ueki M, Sugimoto O (1983) Effective bromocriptine treatment of a pituitary macroadenoma during pregnancy. Obstet Gynecol 61(1):117-121PubMedGoogle Scholar
  146. 146.
    Molitch ME (1996) Evaluation and management of pituitary tumors during pregnancy. Endocr Pract 2(4):287-295PubMedGoogle Scholar
  147. 147.
    Serri O, Rasio E, Beauregard H, Hardy J, Somma M (1983) Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 309(5):280-283PubMedCrossRefGoogle Scholar
  148. 148.
    Molitch ME (1999) Management of prolactinomas during pregnancy. J Reprod Med 44(12 Suppl):1121-1126PubMedGoogle Scholar
  149. 149.
    al-Suleiman SA, Najashi S, Rahman J, Rahman MS (1989) Outcome of treatment with bromocriptine in patients with hyperprolactinaemia. Aust N Z J Obstet Gynaecol 29(2):176-179PubMedCrossRefGoogle Scholar
  150. 150.
    Verhelst J, Abs R (2003) Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2(1):23-32PubMedCrossRefGoogle Scholar
  151. 151.
    Molitch ME (2002) Medical management of prolactin-secreting pituitary adenomas. Pituitary 5(2):55-65PubMedCrossRefGoogle Scholar
  152. 152.
    Acarturk F, Altug N (2001) In-vitro and in-vivo evaluation of a matrix-controlled bromocriptine mesilate-releasing vaginal ring. J Pharm Pharmacol 53(12):1721-1726PubMedCrossRefGoogle Scholar
  153. 153.
    Darwish AM, Farah E, Gadallah WA, Mohammad II (2007) Superiority of newly developed vaginal suppositories over vaginal use of commercial bromocriptine tablets: a randomized controlled clinical trial. Reprod Sci 14(3):280-285PubMedCrossRefGoogle Scholar
  154. 154.
    Ricci G, Giolo E, Nucera G, Pozzobon C, De Seta F, Guaschino S (2001) Pregnancy in hyperprolactinemic infertile women treated with vaginal bromocriptine: report of two cases and review of the literature. Gynecol Obstet Invest 51(4):266-270PubMedCrossRefGoogle Scholar
  155. 155.
    Darwish AM, Hafez E, El-Gebali I, Hassan SB (2005) Evaluation of a novel vaginal bromocriptine mesylate formulation: a pilot study. Fertil Steril 83(4):1053-1055PubMedCrossRefGoogle Scholar
  156. 156.
    Ginsburg J, Hardiman P, Thomas M (1992) Vaginal bromocriptine - clinical and biochemical effects. Gynecol Endocrinol 6(2):119-126PubMedCrossRefGoogle Scholar
  157. 157.
    Vermesh M, Fossum GT, Kletzky OA (1988) Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. Obstet Gynecol 72(5):693-698PubMedGoogle Scholar
  158. 158.
    Katz E, Weiss BE, Hassell A, Schran HF, Adashi EY (1991) Increased circulating levels of bromocriptine after vaginal compared with oral administration. Fertil Steril 55(5):882-884PubMedGoogle Scholar
  159. 159.
    Krupp P, Monka C (1987) Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65(17):823-827PubMedCrossRefGoogle Scholar
  160. 160.
    Calaf Alsina J, Ruiz Balda JA, Romeu Sarrio A et al (2003) Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. BJOG 110(12):1072-1077PubMedGoogle Scholar
  161. 161.
    Chiodini I, Liuzzi A (2003) PRL-secreting pituitary adenomas in pregnancy. J Endocrinol Invest 26(1):96-99PubMedGoogle Scholar
  162. 162.
    de Wit W, Coelingh Bennink HJ, Gerards LJ (1984) Prophylactic bromocriptine treatment during pregnancy in women with macroprolactinomas: report of 13 pregnancies. Br J Obstet Gynaecol 91(11):1059-1069PubMedGoogle Scholar
  163. 163.
    Mattei AM, Ferrari C, Ragni G et al (1984) Serum prolactin and ovarian function after discontinuation of drug treatment for hyperprolactinaemia: a study with bromocriptine and metergoline. Br J Obstet Gynaecol 91(3):244-250PubMedGoogle Scholar
  164. 164.
    Ferrari C, Mattei A, Melis GB et al (1989) Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 68(6):1201-1206PubMedCrossRefGoogle Scholar
  165. 165.
    Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D’Alberton A, Crosignani P (1992) Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 126(6):489-494PubMedGoogle Scholar
  166. 166.
    Ferrari C, Piscitelli G, Crosignani PG (1995) Cabergoline: a new drug for the treatment of hyperprolactinaemia. Hum Reprod 10(7):1647-1652PubMedGoogle Scholar
  167. 167.
    Rains CP, Bryson HM, Fitton A (1995) Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 49(2):255-279Google Scholar
  168. 168.
    Colao A, Lombardi G, Annunziato L (2000) Cabergoline. Expert Opin Pharmacother 1(3):555-574PubMedCrossRefGoogle Scholar
  169. 169.
    Radwanska E, McGarrigle HH, Little V, Lawrence D, Sarris S, Swyer GI (1979) Induction of ovulation in women with hyperprolactinemic amenorrhea using clomiphene and human chorionic gonadotropin of bromocriptine. Fertil Steril 32(2):187-192PubMedGoogle Scholar
  170. 170.
    Aono T, Miyake A, Yasuda TS, Koike K, Kurachi K (1979) Restoration of oestrogen positive feedback effect on LH release by bromocriptine in hyperprolactinaemic patients with galactorrhoea-amenorrhoea. Acta Endocrinol 91(4):591-600PubMedGoogle Scholar
  171. 171.
    Borges LE, Morgante G, Musacchio MC, Petraglia F, De Leo V (2007) New protocol of clomiphene citrate treatment in women with hypothalamic amenorrhea. Gynecol Endocrinol 23(6):343-346PubMedCrossRefGoogle Scholar
  172. 172.
    Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ (1999) Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab 84(1):228-232PubMedCrossRefGoogle Scholar
  173. 173.
    Platteau P, Andersen AN, Balen A et al (2006) Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod 21(7):1798-1804PubMedCrossRefGoogle Scholar
  174. 174.
    Filicori M, Cognigni GE, Pocognoli P et al (2003) Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone. Fertil Steril 80(2):390-397PubMedCrossRefGoogle Scholar
  175. 175.
    Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B (2005) Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril 84(2):394-401PubMedCrossRefGoogle Scholar
  176. 176.
    Kilani Z, Dakkak A, Ghunaim S et al (2003) A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Hum Reprod 18(6):1194-1199PubMedCrossRefGoogle Scholar
  177. 177.
    Wide L, Naessen T, Sundstrom-Poromaa I, Eriksson K (2007) Sulfonation and sialylation of gonadotropins in women during the menstrual cycle, after menopause, and with polycystic ovarian syndrome and in men. J Clin Endocrinol Metab 92(11):4410-4417PubMedCrossRefGoogle Scholar
  178. 178.
    Barrios-De-Tomasi J, Timossi C, Merchant H et al (2002) Assessment of the in vitro and in vivo biological activities of the human follicle-stimulating isohormones. Mol Cell Endocrinol 186(2):189-198PubMedCrossRefGoogle Scholar
  179. 179.
    Andersen CY, Leonardsen L, Ulloa-Aguirre A, Barrios-De-Tomasi J, Kristensen KS, Byskov AG (2001) Effect of different FSH isoforms on cyclic-AMP production by mouse cumulus-oocyte-complexes: a time course study. Mol Hum Reprod 7(2):129-135PubMedCrossRefGoogle Scholar
  180. 180.
    Matikainen T, De Leeuw R, Mannaerts B, Huhtaniemi I (1994) Circulating bioactive and immunoreactive recombinant human follicle stimulating hormone (Org 32489) after administration to gonadotropin-deficient subjects. Fertil Steril 61(1):62-69PubMedGoogle Scholar
  181. 181.
    D’Antonio M, Borrelli F, Datola A et al (1999) Biological characterization of recombinant human follicle stimulating hormone isoforms. Hum Reprod 14(5):1160-1167PubMedCrossRefGoogle Scholar
  182. 182.
    van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW (2003) Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online 7(5):547-557Google Scholar
  183. 183.
    Stokman PG, de Leeuw R, van den Wijngaard HA, Kloosterboer HJ, Vemer HM, Sanders AL (1993) Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. Fertil Steril 60(1):175-178PubMedGoogle Scholar
  184. 184.
    Klein J, Lobel L, Pollak S et al (2003) Development and characterization of a long-acting recombinant hFSH agonist. Hum Reprod 18(1):50-56PubMedCrossRefGoogle Scholar
  185. 185.
    Balasch J, Fabregues F, Casamitjana R, Penarrubia J, Vanrell JA (2003) A pharmacokinetic and endocrine comparison of recombinant follicle-stimulating hormone and human menopausal gonadotrophin in polycystic ovary syndrome. Reprod Biomed Online 6(3):296-301PubMedCrossRefGoogle Scholar
  186. 186.
    Duijkers IJ, Klipping C, Mulders TM, Out HJ, Coelingh Bennink HJ, Vemer HM (1997) Pharmacodynamics and pharmacokinetics after repeated subcutaneous administration of three gonadotrophin preparations. Hum Reprod 12(11):2379-2384PubMedCrossRefGoogle Scholar
  187. 187.
    Voortman G, van de Post J, Schoemaker RC, van Gerven JM (1999) Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon(R)) by Pen-injector and syringe. Hum Reprod 14(7):1698-1702PubMedCrossRefGoogle Scholar
  188. 188.
    Duijkers IJ, Beerens MC, Coelingh Bennink HJ, Huisman JA, Rombout F, Vemer HM (1995) Pharmacokinetics of two human menopausal gonadotrophin preparations after single intravenous administration during pituitary suppression. Hum Reprod 10(6):1367-1372PubMedGoogle Scholar
  189. 189.
    Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, De Bie JJ, Voortman G (2002) Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Hum Reprod 17(8):1987-1993PubMedCrossRefGoogle Scholar
  190. 190.
    Olivares A, Cardenas M, Timossi C, Zarinan T, Diaz-Sanchez V, Ulloa-Aguirre A (2000) Reactivity of different LH and FSH standards and preparations in the world health organization matched reagents for enzyme-linked immunoassays of gonadotrophins. Hum Reprod 15(11):2285-2291PubMedCrossRefGoogle Scholar
  191. 191.
    Fauser BC (1998) Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? Hum Reprod 13 Suppl 3:36-46; discussion 7-51PubMedGoogle Scholar
  192. 192.
    Rose MP, Gaines-Das RE (1998) Characterisation, calibration and comparison by international collaborative study of international standards for the calibration of therapeutic preparations of FSH. J Endocrinol 158(1):97-114PubMedCrossRefGoogle Scholar
  193. 193.
    Mannaerts BM, Rombout F, Out HJ, Coelingh Bennink H (1996) Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy. Hum Reprod Update 2(2):153-161PubMedCrossRefGoogle Scholar
  194. 194.
    le Cotonnec JY, Loumaye E, Porchet HC, Beltrami V, Munafo A (1998) Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil Steril 69(2):201-209PubMedCrossRefGoogle Scholar
  195. 195.
    le Cotonnec JY, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M (1994) Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil Steril 61(4):669-678Google Scholar
  196. 196.
    van Wely M, Bayram N, van der Veen F (2003) Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review. Hum Reprod 18(6):1143-1149PubMedCrossRefGoogle Scholar
  197. 197.
    Balen A, Platteau P, Andersen AN, Devroey P, Helmgaard L, Arce JC (2007) Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial. Hum Reprod 22(7):1816-1823PubMedCrossRefGoogle Scholar
  198. 198.
    van Wely M, Bayram N, van der Veen F, Bossuyt PM (2005) Predicting ongoing pregnancy following ovulation induction with recombinant FSH in women with polycystic ovary syndrome. Hum Reprod 20(7):1827-1832PubMedCrossRefGoogle Scholar
  199. 199.
    Daya S, Gunby J (2000) Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. Cochrane Database Syst Rev 4:CD002810Google Scholar
  200. 200.
    Strowitzki T, Seehaus D, Korell M, Hepp H (1998) Low-dose FSH stimulation in polycystic ovary syndrome: comparison of 3 FSH-preparations. Exp Clin Endocrinol Diab 106(5):435-439CrossRefGoogle Scholar
  201. 201.
    Szilagyi A, Bartfai G, Manfai A, Koloszar S, Pal A, Szabo I (2004) Low-dose ovulation induction with urinary gonadotropins or recombinant follicle stimulating hormone in patients with polycystic ovary syndrome. Gynecol Endocrinol 18(1):17-22PubMedCrossRefGoogle Scholar
  202. 202.
    Daya S (2002) Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil Steril 77(4):711-714PubMedCrossRefGoogle Scholar
  203. 203.
    Steinkampf MP, Hammond KR, Nichols JE, Slayden SH (2003) Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration. Fertil Steril 80(1):99-102PubMedCrossRefGoogle Scholar
  204. 204.
    Rossmanith WG, Sterzik K, Wolf AS (1987) Initial experiences with subcutaneous pulsatile human menopausal gonadotropin administration: successful induction of ovulation in patients with polycystic ovarian disease. Int J Fertil 32(6):460-466PubMedGoogle Scholar
  205. 205.
    Quartero HW, Dixon JE, Westwood O, Hicks B, Chapman MG (1989) Ovulation induction in polycystic ovarian disease by pure FSH (Metrodin). A comparison between chronic low-dose pulsatile administration and i.m. injections. Hum Reprod 4(3):247-249PubMedGoogle Scholar
  206. 206.
    Yuen BH, Pride SM, Callegari PB, Leroux AM, Moon YS (1989) Clinical and endocrine response to pulsatile intravenous gonadotropins in refractory anovulation. Obstet Gynecol 74(5):763-768PubMedGoogle Scholar
  207. 207.
    Dale O, Tanbo T, Lunde O, Abyholm T (1993) Ovulation induction with low-dose follicle-stimulating hormone in women with the polycystic ovary syndrome. Acta Obstet Gynecol Scand 72(1):43-46PubMedCrossRefGoogle Scholar
  208. 208.
    Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV, Mahale SD (2009) Follicle-stimulating hormone receptor polymorphism (Thr(307)Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women. Fertil Steril 91(2):432-439PubMedCrossRefGoogle Scholar
  209. 209.
    Navot D, Margalioth EJ, Laufer N, Brzezinski A, Birkenfeld A, Schenker JG (1987) Periovulatory 17 beta-estradiol pattern in conceptional and nonconceptional cycles during menotropin treatment of anovulatory infertility. Fertil Steril 47(2):234-237PubMedGoogle Scholar
  210. 210.
    Muechler EK, Kohler D, Huang KE (1981) Monitoring of ovulation induction with HMG-HCG therapy by plasma estrogen and progesterone. Int J Fertil 26(4):273-278PubMedGoogle Scholar
  211. 211.
    Haning RV Jr, Levin RM, Behrman HR, Kase NG, Speroff L (1979) Plasma estradiol window and urinary estriol glucuronide determinations for monitoring menotropin induction of ovulation. Obstet Gynecol 54(4):442-447PubMedGoogle Scholar
  212. 212.
    Diamond MP, Wentz AC (1986) Ovulation induction with human menopausal gonadotropins. Obstet Gynecol Surv 41(8):480-490PubMedGoogle Scholar
  213. 213.
    Smith DH, Picker RH, Sinosich M, Saunders DM (1980) Assessment of ovulation by ultrasound and estradiol levels during spontaneous and induced cycles. Fertil Steril 33(4):387-390PubMedGoogle Scholar
  214. 214.
    Aboulghar M (2003) Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS. Hum Reprod 18(6):1140-1141Google Scholar
  215. 215.
    D’Angelo A, Davies R, Salah E, Nix BA, Amso NN (2004) Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study. Fertil Steril 81(2):332-336PubMedCrossRefGoogle Scholar
  216. 216.
    Tur R, Barri PN, Coroleu B, Buxaderas R, Martinez F, Balasch J (2001) Risk factors for high-order multiple implantation after ovarian stimulation with gonadotrophins: evidence from a large series of 1878 consecutive pregnancies in a single centre. Hum Reprod 16(10):2124-2129PubMedCrossRefGoogle Scholar
  217. 217.
    Blankstein J, Shalev J, Saadon T et al (1987) Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil Steril 47(4):597-602PubMedGoogle Scholar
  218. 218.
    Navot D, Goldstein N, Mor-Josef S, Simon A, Relou A, Birkenfeld A (1991) Multiple pregnancies: risk factors and prognostic variables during induction of ovulation with human menopausal gonadotrophins. Hum Reprod 6(8):1152-1155PubMedGoogle Scholar
  219. 219.
    Reuter KL, Cohen S, Furey L, Baker S (1996) Sonographic appearance of the endometrium and ovaries during cycles stimulated with human menopausal gonadotropin. J Reprod Med 41(7):509-514PubMedGoogle Scholar
  220. 220.
    Levy T, Orvieto R, Homburg R, Peleg D, Dekel A, Ben-Rafael Z (1996) Severe ovarian hyperstimulation syndrome despite low plasma oestrogen concentrations in a hypogonadotrophic, hypogonadal patient. Hum Reprod 11(6):1177-1179PubMedGoogle Scholar
  221. 221.
    Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ (1988) Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 159(1):210-215PubMedGoogle Scholar
  222. 222.
    Orvieto R (2003) Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Hum Reprod 18(4):665-667CrossRefGoogle Scholar
  223. 223.
    Lee TH, Liu CH, Huang CC et al (2008) Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 23(1):160-167PubMedCrossRefGoogle Scholar
  224. 224.
    Ludwig M, Jelkmann W, Bauer O, Diedrich K (1994) Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. Hum Reprod 14(10):2437-2441CrossRefGoogle Scholar
  225. 225.
    O’Herlihy C, Pepperell RJ, Robinson HP (1982) Ultrasound timing of human chorionic gonadotropin administration in clomiphene-stimulated cycle. Obstet Gynecol 59(1):40-45PubMedGoogle Scholar
  226. 226.
    Emperaire JC, Edwards RG (2004) Time to revolutionize the triggering of ovulation. Reprod Biomed Online 9(5):480-483PubMedCrossRefGoogle Scholar
  227. 227.
    Van Der Meer M, Hompes PG, De Boer JA, Schats R, Schoemaker J (1998) Cohort size rather than follicle-stimulating hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome. J Clin Endocrinol Metab 83(2):423-426CrossRefGoogle Scholar
  228. 228.
    Lass A, Vassiliev A, Decosterd G, Warne D, Loumaye E (2002) Relationship of baseline ovarian volume to ovarian response in World Health Organization II anovulatory patients who underwent ovulation induction with gonadotropins. Fertil Steril 78(2):265-269PubMedCrossRefGoogle Scholar
  229. 229.
    Imani B, Eijkemans MJ, Faessen GH, Bouchard P, Giudice LC, Fauser BC (2002) Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril 77(1):83-90PubMedCrossRefGoogle Scholar
  230. 230.
    Shoham Z, Patel A, Jacobs HS (1991) Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone. Fertil Steril 55(6):1051-1056PubMedGoogle Scholar
  231. 231.
    Hamilton-Fairley D, Kiddy D, Watson H, Sagle M, Franks S (1991) Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum Reprod 6(8):1095-1099PubMedGoogle Scholar
  232. 232.
    Grigoriou O, Antoniou G, Antonaki V, Patsouras C, Zioris C, Karakitsos P (1996) Low-dose follicle-stimulating hormone treatment for polycystic ovarian disease. Int J Gynaecol Obstet 52(1):55-59PubMedCrossRefGoogle Scholar
  233. 233.
    Ergur AR, Yergok YZ, Ertekin A, Kucuk T, Mungen E, Tutuncu L (1998) Clomiphene citrate-resistant polycystic ovary syndrome. Preventing multifollicular development. J Reprod Med 43(3):185-190Google Scholar
  234. 234.
    Homburg R, Levy T, Ben-Rafael Z (1995) A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril 63(4):729-733PubMedGoogle Scholar
  235. 235.
    Hedon B, Hugues JN, Emperaire JC et al (1998) A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. Hum Reprod 13(1O):2688-2692PubMedGoogle Scholar
  236. 236.
    Strowitzki T, Seehaus D, Korell M, Hepp H (1994) Low-dose follicle stimulating hormone for ovulation induction in polycystic ovary syndrome. J Reprod Med 39(7):499-503PubMedGoogle Scholar
  237. 237.
    Andoh K, Mizunuma H, Liu X, Kamijo T, Yamada K, Ibuki Y (1998) A comparative study of fixed-dose, step-down, and low-dose step-up regimens of human menopausal gonadotropin for patients with polycystic ovary syndrome. Fertil Steril 70(5):840-846PubMedCrossRefGoogle Scholar
  238. 238.
    Balasch J, Fabregues F, Creus M, Casamitjana R, Puerto B, Vanrell JA (2000) Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: a prospective, randomized trial of two starting doses in a chronic low-dose step-up protocol. J Assist Reprod Genet 17(10):561-565PubMedCrossRefGoogle Scholar
  239. 239.
    Gorry A, White DM, Franks S (2006) Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment. Endocrine 30(1):27-33PubMedCrossRefGoogle Scholar
  240. 240.
    Christin-Maitre S, Hugues JN (2003) A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod 18(8):1626-1631PubMedCrossRefGoogle Scholar
  241. 241.
    Buckler HM, Robertson WR, Anderson A, Vickers M, Lambert A (1999) Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon). Hum Reprod 14(12):2969-2973PubMedCrossRefGoogle Scholar
  242. 242.
    Balasch J, Fabregues F, Creus M, Puerto B, Penarrubia J, Vanrell JA (2001) Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens. Hum Reprod 16(4):652-656PubMedCrossRefGoogle Scholar
  243. 243.
    Yong EL, Ng SC, Chan CL, Kumar J, Teo LS, Ratnam SS (1997) Chronic low-dose follicle-stimulating hormone compared with clomiphene/human menopausal gonadotropin for induction of ovulation. Gynecol Endocrinol 11(1):35-42PubMedCrossRefGoogle Scholar
  244. 244.
    Hugues JN, Cedrin-Durnerin I, Howles CM et al (2006) The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study. Hum Reprod 21(11):2817-2822PubMedCrossRefGoogle Scholar
  245. 245.
    Filicori M, Cognigni GE, Pocognoli P et al (2002) Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration. Hum Reprod 17(8):2009-2015PubMedCrossRefGoogle Scholar
  246. 246.
    Filicori M, Cognigni GE, Samara A et al (2002) The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update 8(6):543-557PubMedCrossRefGoogle Scholar
  247. 247.
    Lee KL, Couchman GM, Walmer DK (2005) Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation. J Assist Reprod Genet 22(1):37-40PubMedCrossRefGoogle Scholar
  248. 248.
    De Leo V, la Marca A, Ditto A, Morgante G, Cianci A (1999) Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 72(2):282-285PubMedCrossRefGoogle Scholar
  249. 249.
    Palomba S, Falbo A, Orio F Jr et al (2005) A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum Reprod 20(10):2879-2886PubMedCrossRefGoogle Scholar
  250. 250.
    Kistner RW (1976) Sequential use of clomiphene citrate and human menopausal gonadotropin in ovulation induction. Fertil Steril 27(1):72-82PubMedGoogle Scholar
  251. 251.
    March CM, Tredway DR, Mishell DR Jr (1976) Effect of clomiphene citrate upon amount and duration of human menopausal gonadotropin therapy. Am J Obstet Gynecol 125(5):699-704PubMedGoogle Scholar
  252. 252.
    Kemmann E, Jones JR (1983) Sequential clomiphene citrate-menotropin therapy for induction or enhancement of ovulation. Fertil Steril 39(6):772-779PubMedGoogle Scholar
  253. 253.
    Mitwally MF, Casper RF (2004) Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig 11(6):406-415PubMedCrossRefGoogle Scholar
  254. 254.
    Nakamura Y, Yamada H, Yoshida K et al (1990) Induction of ovulation with pulsatile subcutaneous administration of human menopausal gonadotropin in patients with polycystic ovary syndrome. Horm Res 33(Suppl 2):43-48PubMedCrossRefGoogle Scholar
  255. 255.
    Check JH, Katsoff B (2008) Ovulation induction and pregnancy in a woman with premature menopause following gonadotropin suppression with the gonadotropin releasing hormone antagonist, cetrorelix - a case report. Clin Exp Obstet Gynecol 35(1):10-12PubMedGoogle Scholar
  256. 256.
    Check ML, Check JH, Kaplan H (2004) Pregnancy despite imminent ovarian failure and extremely high endogenous gonadotropins and therapeutic strategies: case report and review. Clin Exp Obstet Gynecol 31(4):299-301PubMedGoogle Scholar
  257. 257.
    Bidet M, Bachelot A, Touraine P (2008) Premature ovarian failure: predictability of intermittent ovarian function and response to ovulation induction agents. Curr Opin Obstet Gynecol 20(4):416-420PubMedCrossRefGoogle Scholar
  258. 258.
    van Kasteren YM, Hoek A, Schoemaker J (1995) Ovulation induction in premature ovarian failure: a placebo-controlled randomized trial combining pituitary suppression with gonadotropin stimulation. Fertil Steril 64(2):273-278PubMedGoogle Scholar
  259. 259.
    Badawy A, Goda H, Ragab A (2007) Induction of ovulation in idiopathic premature ovarian failure: a randomized double-blind trial. Reprod Biomed Online 15(2):215-219PubMedCrossRefGoogle Scholar
  260. 260.
    Tartagni M, Cicinelli E, De Pergola G, De Salvia MA, Lavopa C, Loverro G (2007) Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial. Fertil Steril 87(4):858-861PubMedCrossRefGoogle Scholar
  261. 261.
    Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG (1994) Ovarian tumors in a cohort of infertile women. N Engl J Med 331(12):771-776PubMedCrossRefGoogle Scholar
  262. 262.
    Whittemore AS (1994) The risk of ovarian cancer after treatment for infertility. N Engl J Med 331(12):805-806PubMedCrossRefGoogle Scholar
  263. 263.
    Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136(10):1184-1203Google Scholar
  264. 264.
    Dor J, Lerner-Geva L, Rabinovici J et al (2002) Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 77(2):324-327PubMedCrossRefGoogle Scholar
  265. 265.
    Klip H, Burger CW, Kenemans P, van Leeuwen FE (2000) Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes Control 11(4):319-344PubMedCrossRefGoogle Scholar
  266. 266.
    Rossing MA, Tang MT, Flagg EW, Weiss LK, Wicklund KG (2004) A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 160(11):1070-1078PubMedCrossRefGoogle Scholar
  267. 267.
    Meirow D, Schenker JG (1996) The link between female infertility and cancer: epidemiology and possible aetiologies. Hum Reprod Update 2(1):63-75PubMedCrossRefGoogle Scholar
  268. 268.
    Kashyap S, Moher D, Fung MF, Rosenwaks Z (2004) Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 103(4):785-794PubMedGoogle Scholar
  269. 269.
    Ayhan A, Salman MC, Celik H, Dursun P, Ozyuncu O, Gultekin M (2004) Association between fertility drugs and gynecologic cancers, breast cancer, and childhood cancers. Acta Obstet Gynecol Scand 83(12):1104-1111PubMedGoogle Scholar
  270. 270.
    Brinton L (2007) Long-term effects of ovulation-stimulating drugs on cancer risk. Reprod Biomed Online 15(1):38-44PubMedCrossRefGoogle Scholar
  271. 271.
    Brinton LA, Lamb EJ, Moghissi KS et al (2004) Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 103(6):1194-1203PubMedGoogle Scholar
  272. 272.
    Brinton LA, Moghissi KS, Scoccia B, Westhoff CL, Lamb EJ (2005) Ovulation induction and cancer risk. Fertil Steril 83(2):261-274; quiz 525-526PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Utah Center for Reproductive Medicine, Department of Obstetrics and GynecologyUniversity of Utah School of MedicineSalt Lake CityUSA

Personalised recommendations